| | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | | | |
---|
What is an ATC-Code? | ATC-Overview |
|
| | IP | CI | | Aldomet 250 | 100 Tablet(s) | 20.28 | 40.25 | k.A. | | Coated tablets: Methyldopum Anhydricum 250 mg | Future Health Pharma GmbH | B | FB | | G |  |
|
| | IP | | | Catapresan | 5 ampoule(s) | PR | 19.10 | k.A. | | Injection solution: Clonidini Hydrochloridum | CPS Cito Pharma Services GmbH | B | FB | | G |  |
| | IP | CI | | Catapresan - T | 100 Tablet(s) | PR | PR | k.A. | | Tablets: Clonidini Hydrochloridum | CPS Cito Pharma Services GmbH | B | FB | | G |  |
| | | | | Catapresan Depot | 30 Capsule(s) | PR | 24.55 | k.A. | | Delayed release capsules: Clonidini Hydrochloridum | Boehringer Ingelheim (Schweiz) GmbH | B | FB | | G |  |
|
L | | IP | CI | | Intuniv 1 mg | 7 | 17.74 | 35.70 | 10 % | | Delayed release tablets: Guanfacinum 1 mg | Takeda Pharma AG | B / SL | FB | | G |  |
L | | IP | CI | | Intuniv 1 mg | 28 | 70.92 | 93.55 | 10 % | | Delayed release tablets: Guanfacinum 1 mg | Takeda Pharma AG | B / SL | FB | | G |  |
L | | IP | CI | | Intuniv 2 mg | 7 | 18.10 | 36.10 | 10 % | | Delayed release tablets: Guanfacinum 2 mg | Takeda Pharma AG | B / SL | FB | | G |  |
L | | IP | CI | | Intuniv 2 mg | 28 | 72.41 | 95.15 | 10 % | | Delayed release tablets: Guanfacinum 2 mg | Takeda Pharma AG | B / SL | FB | | G |  |
L | | IP | CI | | Intuniv 3 mg | 28 | 75.76 | 98.80 | 10 % | | Delayed release tablets: Guanfacinum 3 mg | Takeda Pharma AG | B / SL | FB | | G |  |
L | | IP | CI | | Intuniv 4 mg | 28 | 81.66 | 105.25 | 10 % | | Delayed release tablets: Guanfacinum 4 mg | Takeda Pharma AG | B / SL | FB | | G |  |
| | IP | | | Intuniv 2 mg | 84 | PR | PR | k.A. | | Delayed release tablets: Guanfacinum 2 mg | Takeda Pharma AG | B | FB | | G |  |
| | IP | | | Intuniv 3 mg | 84 | PR | PR | k.A. | | Delayed release tablets: Guanfacinum 3 mg | Takeda Pharma AG | B | FB | | G |  |
| | IP | | | Intuniv 4 mg | 84 | PR | PR | k.A. | | Delayed release tablets: Guanfacinum 4 mg | Takeda Pharma AG | B | FB | | G |  |
|
L | | IP | CI | | Physiotens mite 0,2 mg | 28 Tablet(s) | 6.91 | 16.75 | 10 % | | Coated tablets: Moxonidinum | Viatris Pharma GmbH | B / SL | FB | | G |  |
L | | IP | CI | | Physiotens mite 0,2 mg | 98 Tablet(s) | 20.81 | 39.05 | 10 % | | Coated tablets: Moxonidinum | Viatris Pharma GmbH | B / SL | FB | | G |  |
L | | IP | CI | | Physiotens 0,3 mg | 28 Tablet(s) | 9.07 | 26.30 | 10 % | | Coated tablets: Moxonidinum | Viatris Pharma GmbH | B / SL | FB | | G |  |
L | | IP | CI | | Physiotens 0,3 mg | 98 Tablet(s) | 29.42 | 48.40 | 10 % | | Coated tablets: Moxonidinum | Viatris Pharma GmbH | B / SL | FB | | G |  |
L | | IP | CI | | Physiotens forte 0,4 mg | 28 Tablet(s) | 10.40 | 27.75 | 10 % | | Coated tablets: Moxonidinum | Viatris Pharma GmbH | B / SL | FB | | G |  |
L | | IP | CI | | Physiotens forte 0,4 mg | 98 Tablet(s) | 34.01 | 53.40 | 10 % | | Coated tablets: Moxonidinum | Viatris Pharma GmbH | B / SL | FB | | G |  |
|
L | | IP | CI | | Cardura CR 4 mg | 30 Tablet(s) | 10.62 | 27.85 | 10 % | | Coated tablets: Doxazosinum 4 mg | Viatris Pharma GmbH | B / SL / SO | FB | | G |  |
L | | IP | CI | | Cardura CR 4 mg | 100 Tablet(s) | 32.97 | 52.05 | 10 % | | Coated tablets: Doxazosinum 4 mg | Viatris Pharma GmbH | B / SL / SO | FB | | G |  |
L | | IP | CI | | Cardura CR 8 mg | 100 Tablet(s) | 48.28 | 68.55 | 10 % | | Coated tablets: Doxazosinum 8 mg | Viatris Pharma GmbH | B / SL / SO | FB | | G |  |
L | | IP | CI | | Doxazosin retard Zentiva 4 mg | 28 | 8.92 | 26.10 | 10 % | | Coated tablets: Doxazosinum 4 mg | Helvepharm AG | B / SL / SG | FB | | G |  |
L | | IP | CI | | Doxazosin retard Zentiva 4 mg | 98 | 29.08 | 48.05 | 10 % | | Coated tablets: Doxazosinum 4 mg | Helvepharm AG | B / SL / SG | FB | | G |  |
L | | IP | CI | | Doxazosin retard Zentiva 8 mg | 28 | 11.58 | 29.00 | 10 % | | Coated tablets: Doxazosinum 8 mg | Helvepharm AG | B / SL / SG | FB | | G |  |
L | | IP | CI | | Doxazosin retard Zentiva 8 mg | 98 | 42.59 | 62.75 | 10 % | | Coated tablets: Doxazosinum 8 mg | Helvepharm AG | B / SL / SG | FB | | G |  |
|
| | IP | | | Ebrantil 50 mg | 5 1 ampoule(s) à 10 ml | PR | 101.00 | k.A. | | Injection solution: Urapidilum 50mg / 10ml | Cheplapharm Schweiz GmbH | B | FB | | G |  |
| | IP | | | Urapidil Stragen i.v. 25 mg | 5 x 5 ml | PR | PR | k.A. | | Injection solution: Urapidilum 25mg / 5ml | Stragen Pharma SA | B | FB | | G |  |
| | IP | | | Urapidil Stragen i.v. 50 mg | 5 x 10 ml | PR | PR | k.A. | | Injection solution: Urapidilum 50mg / 10ml | Stragen Pharma SA | B | FB | | G |  |
|
| | IP | | | Nipruss 60 mg | 5 | PR | PR | k.A. | | Lyophilisate: Natrii Nitroprussias Dihydricus 60 mg | Ospedalia AG | A | FB | | G |  |
|
| | IP | | | Winrevair 45 mg | | PR | PR | k.A. | | Dry substance: Sotaterceptum 45 mg | MSD Merck Sharp & Dohme AG | B | FB | | G |  |
| | IP | | | Winrevair 45 mg | 2 | PR | PR | k.A. | | Dry substance: Sotaterceptum 45 mg | MSD Merck Sharp & Dohme AG | B | FB | | G |  |
| | IP | | | Winrevair 60 mg | | PR | PR | k.A. | | Dry substance: Sotaterceptum 60 mg | MSD Merck Sharp & Dohme AG | B | FB | | G |  |
| | IP | | | Winrevair 60 mg | 2 | PR | PR | k.A. | | Dry substance: Sotaterceptum 60 mg | MSD Merck Sharp & Dohme AG | B | FB | | G |  |
|
| | IP | CI | | Tracleer 62,5 mg | 56 Tablet(s) | 922.05 | 1013.50 | 10 % | | Coated tablets: Bosentanum 62.5 mg | Janssen-Cilag AG | B / SL / SO | FB | | G |  |
| | IP | CI | | Tracleer 62,5 mg | 56 | 922.05 | 1013.50 | 10 % | | Coated tablets: Bosentanum 62.5 mg | Janssen-Cilag AG | B / SL / SO | FB | | G |  |
| | IP | CI | | Tracleer 125 mg | 56 Tablet(s) | 922.05 | 1013.50 | 10 % | | Coated tablets: Bosentanum 125 mg | Janssen-Cilag AG | B / SL / SO | FB | | G |  |
| | IP | CI | | Tracleer 125 mg | 56 | 922.05 | 1013.50 | 10 % | | Coated tablets: Bosentanum 125 mg | Janssen-Cilag AG | B / SL / SO | FB | | G |  |
| | IP | CI | | Bosentan-Mepha 62.5 mg | 56 | 829.85 | 918.95 | 10 % | | Coated tablets: Bosentanum 62.5 mg | Mepha Pharma AG | ● B / SL / SG | FB | | G |  |
| | IP | CI | | Bosentan-Mepha 125 mg | 56 | 829.85 | 918.95 | 10 % | | Coated tablets: Bosentanum 125 mg | Mepha Pharma AG | ● B / SL / SG | FB | | G |  |
| | IP | CI | | Tracleer | 56 Tablet(s) | PR | PR | k.A. | | Dispersible Tablets: Bosentanum 32 mg | Janssen-Cilag AG | B | FB | | G |  |
| | IP | CI | | Bosentan-Mepha 62.5 mg | 14 | PR | PR | k.A. | | Coated tablets: Bosentanum 62.5 mg | Mepha Pharma AG | B | FB | | G |  |
| | IP | CI | | Bosentan-Mepha 125 mg | 14 | PR | PR | k.A. | | Coated tablets: Bosentanum 125 mg | Mepha Pharma AG | B | FB | | G |  |
|
L | | IP | CI | | Volibris 5 mg | 30 Tablet(s) | 1089.60 | 1195.35 | 10 % | | Coated tablets: Ambrisentanum 5 mg | GlaxoSmithKline AG | B / SL / SO | FB | | G |  |
L | | IP | CI | | Volibris 10 mg | 30 Tablet(s) | 1089.60 | 1195.35 | 10 % | | Coated tablets: Ambrisentanum 10 mg | GlaxoSmithKline AG | B / SL / SO | FB | | G |  |
L | | IP | CI | | Ambrisentan Devatis 5 mg | 30 | 990.57 | 1093.70 | 10 % | | Coated tablets: Ambrisentanum 5 mg | Devatis AG | B / SL / SG | FB | | G |  |
L | | IP | | | Ambrisentan Devatis 10 mg | 30 | 990.57 | 1093.70 | 10 % | | Coated tablets: Ambrisentanum 10 mg | Devatis AG | B / SL / SG | FB | | G |  |
L | | IP | CI | | Ambrisentan OrPha 5 mg | 30 | 990.57 | 1093.70 | 10 % | | Coated tablets: Ambrisentanum 5 mg | OrPha Swiss GmbH | B / SL / SG | FB | | G |  |
L | | IP | | | Ambrisentan OrPha 10 mg | 30 | 990.57 | 1093.70 | 10 % | | Coated tablets: Ambrisentanum 10 mg | OrPha Swiss GmbH | B / SL / SG | FB | | G |  |
L | | IP | CI | | Ambrisentan-Mepha 5 mg | 30 | 990.57 | 1093.70 | 10 % | | Coated tablets: Ambrisentanum 5 mg | Mepha Pharma AG | B / SL / SG | FB | | G |  |
L | | IP | | | Ambrisentan-Mepha 10 mg | 30 | 990.57 | 1093.70 | 10 % | | Coated tablets: Ambrisentanum 10 mg | Mepha Pharma AG | B / SL / SG | FB | | G |  |
| | IP | CI | | Ambrisentan Devatis 5 mg | 10 | PR | PR | k.A. | | Coated tablets: Ambrisentanum 5 mg | Devatis AG | B | FB | | G |  |
| | IP | | | Ambrisentan Devatis 10 mg | 10 | PR | PR | k.A. | | Coated tablets: Ambrisentanum 10 mg | Devatis AG | B | FB | | G |  |
|
L | | IP | CI | PP | Opsumit 10 mg | 30 Tablet(s) | 2800.97 | 3062.65 | 10 % | | Coated tablets: Macitentanum 10 mg | Actelion Pharmaceuticals Ltd | B / SL | FB | | G |  |
|
L | | IP | CI | PP | Adempas 0.5 mg | 42 Tablet(s) | 1288.67 | 1417.90 | 10 % | | Coated tablets: Riociguatum | Bayer (Schweiz) AG | B / SL | FB | | G |  |
L | | IP | CI | PP | Adempas 1 mg | 42 Tablet(s) | 1288.67 | 1417.90 | 10 % | | Coated tablets: Riociguatum 1 mg | Bayer (Schweiz) AG | B / SL | FB | | G |  |
L | | IP | CI | PP | Adempas 1.5 mg | 42 Tablet(s) | 1288.67 | 1417.90 | 10 % | | Coated tablets: Riociguatum 1.5 mg | Bayer (Schweiz) AG | B / SL | FB | | G |  |
L | | IP | CI | PP | Adempas 1.5 mg | 84 Tablet(s) | 2577.34 | 2819.45 | 10 % | | Coated tablets: Riociguatum 1.5 mg | Bayer (Schweiz) AG | B / SL | FB | | G |  |
L | | IP | CI | PP | Adempas 2 mg | 42 Tablet(s) | 1288.67 | 1417.90 | 10 % | | Coated tablets: Riociguatum 2 mg | Bayer (Schweiz) AG | B / SL | FB | | G |  |
L | | IP | CI | PP | Adempas 2 mg | 84 Tablet(s) | 2577.34 | 2819.45 | 10 % | | Coated tablets: Riociguatum 2 mg | Bayer (Schweiz) AG | B / SL | FB | | G |  |
L | | IP | CI | PP | Adempas 2.5 mg | 42 Tablet(s) | 1288.67 | 1417.90 | 10 % | | Coated tablets: Riociguatum 2.5 mg | Bayer (Schweiz) AG | B / SL | FB | | G |  |
L | | IP | CI | PP | Adempas 2.5 mg | 84 Tablet(s) | 2577.34 | 2819.45 | 10 % | | Coated tablets: Riociguatum 2.5 mg | Bayer (Schweiz) AG | B / SL | FB | | G |  |
| | IP | CI | PP | Adempas 0.5 mg | 84 Tablet(s) | PR | PR | k.A. | | Coated tablets: Riociguatum | Bayer (Schweiz) AG | B | FB | | G |  |
| | IP | CI | PP | Adempas 1 mg | 84 Tablet(s) | 2577.34 | 2819.45 | k.A. | | Coated tablets: Riociguatum 1 mg | Bayer (Schweiz) AG | B | FB | | G |  |
|
L | | IP | CI | | Winrevair 45 mg | | 5956.94 | 6419.60 | 10 % | | Lyophilisate and solvent: Sotaterceptum 45 mg | MSD Merck Sharp & Dohme AG | B / SL | FB | | G |  |
L | | IP | CI | | Winrevair 45 mg | 2 | 11913.87 | 12531.45 | 10 % | | Lyophilisate and solvent: Sotaterceptum 45 mg | MSD Merck Sharp & Dohme AG | B / SL | FB | | G |  |
L | | IP | | | Winrevair 60 mg | | 7942.58 | 8456.90 | 10 % | | Lyophilisate and solvent: Sotaterceptum 60 mg | MSD Merck Sharp & Dohme AG | B / SL | FB | | G |  |
L | | IP | | | Winrevair 60 mg | 2 | 15885.16 | 16605.95 | 10 % | | Lyophilisate and solvent: Sotaterceptum 60 mg | MSD Merck Sharp & Dohme AG | B / SL | FB | | G |  |
|
L | | IP | CI | | Yuvanci 10 mg/40 mg | 30 | 2736.57 | 2992.60 | 10 % | | Coated tablets: 2 Active Agents | Janssen-Cilag AG | B / SL | FB | | G |  |
|
| | | CI | H | Co-Hypert | 100 ml | PR | 27.20 | k.A. | | Tropfen zum Einnehmen: 7 Active Agents | ebi-pharm ag | B | FB | | G |  |